K. Graudenz

Phase 1, open-label, dose-escalation study of sorafenib in combination with eribulin in patients with advanced, metastatic, or refractory solid tumors

F. Marmé, J. Lettieri, C. Gomez-Roca, 2018, Cancer Chemotherapy and Pharmacology.

Evaluation of Clinically Relevant Drug–Drug Interactions and Population Pharmacokinetics of Darolutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Results of Pre-Specified and Post Hoc Analyses of the Phase III ARAMIS Trial

T. Tammela, B. Ploeger, O. Petrenciuc, 2019, Targeted Oncology.

Significant localized reduction in cerebral blood flow (CBF) in regions relevant to cognitive function with enzalutamide (ENZA) compared to darolutamide (DARO) and placebo (PBO) in healthy volunteers.

Steven C. R. Williams, O. O'Daly, Caroline Wooldridge, 2020 .

Drug–Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies

Michaela Bairlein, M. Koskinen, T. Korjamo, 2019, European Journal of Drug Metabolism and Pharmacokinetics.

[Diffused traumatic dirt and decorative tattooing. Removal by Q-switched lasers].

C. Raulin, K. Graudenz, B. Greve, 2003, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete.